Serum procalcitonine (PCT) as a marker of respiratory infection by pseudomonas aeruginosa (PA) in patients with COPD or bronchiectasis

V. Giraud, D. Cobarzan, H. Puy, A. Beauchet, B. Heym, T. Chinet (Boulogne, France)

Source: Annual Congress 2009 - Biomarkers and biology in COPD
Session: Biomarkers and biology in COPD
Session type: E-Communication Session
Number: 429
Disease area: Airway diseases, Respiratory infections

Congress or journal article abstractE-poster

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
V. Giraud, D. Cobarzan, H. Puy, A. Beauchet, B. Heym, T. Chinet (Boulogne, France). Serum procalcitonine (PCT) as a marker of respiratory infection by pseudomonas aeruginosa (PA) in patients with COPD or bronchiectasis. Eur Respir J 2009; 34: Suppl. 53, 429

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
The discriminatory value of procalcitonin (PCT) and C-reactive protein (CRP) levels in HIV-seropositive patients presenting with community acquired pneumonia (CAP) due to pulmonary tuberculosis (PTB) compared with patients with pneumococcal pneumonia
Source: Eur Respir J 2004; 24: Suppl. 48, 241s
Year: 2004

Serum procalcitonin (PCT-Q) as a diagnostic tool for bacterial lower respiratory tract infection among COPD patients with acute exacerbation
Source: Annual Congress 2013 –Difficult and rare respiratory infections
Year: 2013


Serum procalcitonin (PCT) as a marker of the severity and prognosis of ventilator-associated pneumonia (VAP)
Source: Annual Congress 2007 - Diagnostic markers and therapy in hospital-acquired pneumonia
Year: 2007


Surfactant protein D (SPD) and C-reactive protein (CRP) in patient with low respiratory tract infections (LRTI)
Source: Annual Congress 2013 –Lung infections: a clinical point of view
Year: 2013

Changes in levels of inflammatory markers (procalcitonin, C-reactive protein) in pregnant with community-acquired pneumonia (CAP)
Source: International Congress 2016 – Community-acquired pneumonia: risk classes and management issues
Year: 2016


C-reactive protein as severity biomarker in patients with community-acquired pneumonia (CAP)
Source: Eur Respir J 2005; 26: Suppl. 49, 545s
Year: 2005

Could procalcitonin (PCT) be a marker of effectiveness of antibiotic treatment (ABT) in pregnant with not severe community-acquired pneumonia (CAP)?
Source: International Congress 2015 – Healthcare organisation and appropriateness in lung disorders
Year: 2015


The difference between surfactant protein D (SPD) and C-reactive protein (CRP) levels in patients (pts) with chronic obstructive pulmonary disease acute exacerbations (AE COPD) and community acquired pneumonia (CAP)
Source: International Congress 2014 – Clinical presentations
Year: 2014


Serum C-reactive protein (CRP) as a marker of the severity and prognosis of ventilator-associated pneumonia (VAP)
Source: Annual Congress 2007 - Diagnostic markers and therapy in hospital-acquired pneumonia
Year: 2007


Evaluation of procalcitonin (PCT) and neopterin levels in acute exacerbations of COPD
Source: Annual Congress 2005 - Acute and chronic infections in COPD
Year: 2005


Procalcitonin (PCT) and C-reactive protein (CRP) as markers of the differential diagnosis of severe community acquired pneumonia (sCAP)
Source: Annual Congress 2013 –Respiratory infections: a combination of problems needing early treatment
Year: 2013


Lung function, symptoms and inflammatory biomarkers in patients with bronchiectasis (brx) with and without chronic pseudomonas aeruginosa (psa) colonisation
Source: Annual Congress 2009 - Translational research/biomarkers
Year: 2009


Performance of rapid, bedside whole blood C-reactive protein (CRP) test as a diagnostic test for bacterial infection and pneumonia in patients with acute exacerbation of chronic obstructive pulmonary disease (AE COPD)
Source: Eur Respir J 2007; 30: Suppl. 51, 557s
Year: 2007

Serum procalcitonin in pneumococcal pneumonia in children
Source: Eur Respir J 2001; 17: 623-627
Year: 2001



C-reactive protein (C-RP) in patients with chronic heart failure (CHF) and community-acquired pneumonia (CAP): usefulness to guide antibiotic prescription
Source: International Congress 2018 – Predicting the future: biomarkers of respiratory infection
Year: 2018


Predictive value of plasma D-dimer in patients with community-acquired pneumonia (CAP)
Source: Annual Congress 2010 - The prognosis of community-acquired pneumonia: old and new markers of severity
Year: 2010


Procalcitonin and C-reactive protein levels in HIV-positive subjects with tuberculosis and pneumonia
Source: Eur Respir J 2005; 25: 688-692
Year: 2005



C-reactive protein (CRP) as a marker of disease severity in community acquired pneumonia patients with sepsis
Source: Annual Congress 2012 - Infections and sepsis in the ICU
Year: 2012


Chlamydia pneumonia (CP), Mycoplasma pneumonia (MP) and virus antibody titres in acute exacerbations of asthma (BA) and chronic bronchitis (COPD)
Source: Eur Respir J 2001; 18: Suppl. 33, 234s
Year: 2001

Serum procalcitonin concentrations in children with pulmonary tuberculosis, tuberculous infection and lober pneumonia
Source: Eur Respir J 2003; 22: Suppl. 45, 176s
Year: 2003